Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor infiltrating lymphocytes TBio-4101

A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patient's resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs TBio-4101 specifically recognize and kill the patient's tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous selected and expanded TILs TBio-4101 autologous selected and expanded tumor infiltrating lymphocytes TBio-4101 autologous TILs TBio-4101
Code name:	TBio 4101 TBio-4101 TBio4101

autologous tumor infiltrating lymphocytes TBio-4101

Search NCI's Drug Dictionary